GMAB [NASD]
Genmab A/S
Index- P/E30.97 EPS (ttm)1.26 Insider Own- Shs Outstand652.85M Perf Week-1.38%
Market Cap25.82B Forward P/E4.61 EPS next Y8.45 Insider Trans- Shs Float651.77M Perf Month-9.98%
Income829.00M PEG1.15 EPS next Q3.23 Inst Own6.90% Short Float / Ratio0.48% / 4.77 Perf Quarter-3.35%
Sales1.76B P/S14.69 EPS this Y-36.90% Inst Trans24.39% Short Interest3.13M Perf Half Y9.66%
Book/sh5.99 P/B6.50 EPS next Y1.80% ROA21.00% Target Price43.75 Perf Year11.36%
Cash/sh5.26 P/C7.40 EPS next 5Y27.00% ROE23.50% 52W Range26.19 - 47.50 Perf YTD-8.90%
Dividend- P/FCF50.60 EPS past 5Y-37.63% ROI9.00% 52W High-18.72% Beta0.78
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low47.42% ATR0.84
Employees1560 Current Ratio9.60 Sales Q/Q76.90% Oper. Margin37.50% RSI (14)37.94 Volatility1.67% 1.79%
OptionableNo Debt/Eq0.02 EPS Q/Q190.80% Profit Margin47.20% Rel Volume0.52 Prev Close38.93
ShortableYes LT Debt/Eq0.02 Earnings- Payout0.00% Avg Volume654.64K Price38.61
Recom2.60 SMA20-2.66% SMA50-9.05% SMA2005.32% Volume151,764 Change-0.82%
Dec-20-22Downgrade Citigroup Buy → Neutral
Nov-14-22Initiated William Blair Mkt Perform
Nov-11-22Downgrade Deutsche Bank Buy → Hold
Jun-24-22Initiated BMO Capital Markets Market Perform $34.73
May-02-22Initiated Cowen Market Perform $38
Mar-16-22Upgrade UBS Neutral → Buy
Jan-31-22Upgrade H.C. Wainwright Neutral → Buy $47
Jan-03-22Downgrade Guggenheim Buy → Neutral
Dec-01-21Initiated Berenberg Sell
Sep-16-21Downgrade Jefferies Buy → Hold $45.50 → $48
Show Previous Ratings
Jan-24-23 02:00PM
06:27AM
Jan-23-23 11:40AM
Jan-20-23 07:04AM
Jan-19-23 11:00AM
12:31PM Loading…
Jan-03-23 12:31PM
Jan-02-23 07:56AM
Dec-21-22 07:00AM
07:00AM
Dec-14-22 03:20PM
Dec-13-22 03:52PM
03:05PM
02:58PM
11:40AM
10:05AM
09:40AM Loading…
Dec-12-22 09:40AM
08:23AM
Dec-11-22 05:30PM
Dec-09-22 05:42PM
Dec-08-22 06:45AM
Dec-05-22 09:15AM
08:46AM
Dec-02-22 03:01PM
09:15AM
08:04AM
Dec-01-22 07:54AM
Nov-24-22 09:40AM
Nov-23-22 02:56PM
09:36AM
Nov-22-22 06:15AM
02:44PM Loading…
Nov-21-22 02:44PM
02:39PM
08:00AM
Nov-17-22 03:17PM
12:20PM
09:15AM
Nov-15-22 01:54PM
Nov-14-22 12:30PM
Nov-11-22 11:40AM
Nov-10-22 08:27AM
Nov-09-22 11:01AM
Nov-08-22 09:40AM
08:42AM
Nov-03-22 12:45PM
09:01AM
Oct-28-22 08:45AM
08:45AM
Oct-25-22 05:40AM
Oct-21-22 09:11AM
Oct-18-22 06:35AM
Oct-17-22 11:40AM
Oct-05-22 03:56PM
Sep-27-22 12:43PM
08:00AM
Sep-20-22 03:20PM
Sep-06-22 10:53AM
Sep-01-22 12:27PM
Aug-29-22 05:04AM
Aug-24-22 02:52PM
Aug-22-22 03:39PM
05:50AM
Aug-17-22 01:19PM
Aug-16-22 02:26PM
02:22PM
Aug-15-22 03:42AM
Aug-10-22 10:30PM
11:01AM
Aug-08-22 12:33PM
04:18AM
Aug-05-22 09:57AM
06:45AM
Aug-02-22 02:46PM
Aug-01-22 07:41AM
Jul-25-22 07:50AM
Jul-20-22 01:03PM
Jul-19-22 06:33AM
Jul-18-22 11:05AM
10:05AM
07:27AM
Jul-11-22 11:28AM
04:50AM
Jul-05-22 02:05PM
Jul-04-22 04:16AM
Jul-01-22 10:15AM
Jun-30-22 02:24PM
Jun-27-22 04:09AM
Jun-23-22 11:55AM
Jun-20-22 10:35AM
Jun-17-22 10:38AM
Jun-13-22 12:25PM
Jun-11-22 08:45AM
08:45AM
Jun-09-22 05:17PM
02:57PM
Jun-08-22 02:32PM
Jun-06-22 11:00AM
11:00AM
Jun-01-22 12:21PM
May-26-22 05:00PM
05:00PM
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.